{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:12:45Z","timestamp":1788369165676,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Philogen"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.leukres.2015.04.005","type":"journal-article","created":{"date-parts":[[2015,4,18]],"date-time":"2015-04-18T03:07:26Z","timestamp":1429326446000},"page":"739-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2501-9480","authenticated-orcid":false,"given":"Niklas","family":"B\u00f6rschel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-2731","authenticated-orcid":false,"given":"Christian","family":"Schw\u00f6ppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Zerbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"Angenendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8216-9560","authenticated-orcid":false,"given":"Giuliano","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf M.","family":"Mesters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2015.04.005_bib0240","first-page":"3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","author":"Armitage","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.04.005_bib0245","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.04.005_bib0250","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2015.04.005_bib0255","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2015.04.005_bib0260","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"New Engl J Med"},{"issue":"February (2)","key":"10.1016\/j.leukres.2015.04.005_bib0265","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrd1957","article-title":"Antibody targeted drugs as cancer therapeutics","volume":"5","author":"Schrama","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"May (5)","key":"10.1016\/j.leukres.2015.04.005_bib0270","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri1837","article-title":"Potent antibody therapeutics by design","volume":"6","author":"Carter","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.leukres.2015.04.005_bib0275","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-3-540-78281-0_12","article-title":"Antibody-based vascular tumor targeting","volume":"180","author":"Schliemann","year":"2010","journal-title":"Recent Results Cancer Res"},{"issue":"June (6)","key":"10.1016\/j.leukres.2015.04.005_bib0280","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nrc1627","article-title":"Tumour vascular targeting","volume":"5","author":"Neri","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"January (2)","key":"10.1016\/j.leukres.2015.04.005_bib0285","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1158\/1078-0432.CCR-0642-03","article-title":"Vascular targeting agents as cancer therapeutics","volume":"10","author":"Thorpe","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2015.04.005_bib0290","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1083\/jcb.108.3.1139","article-title":"A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors","volume":"108","author":"Carnemolla","year":"1989","journal-title":"J Cell Biol"},{"key":"10.1016\/j.leukres.2015.04.005_bib0295","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/14728222.9.3.491","article-title":"ED-B fibronectin as a target for antibody-based cancer treatments","volume":"9","author":"Menrad","year":"2005","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.leukres.2015.04.005_bib0300","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1182\/blood-2008-05-160747","article-title":"Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2","volume":"113","author":"Schliemann","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.04.005_bib0305","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2008-06-160416","article-title":"Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients","volume":"113","author":"Sauer","year":"2009","journal-title":"Blood"},{"issue":"June (6)","key":"10.1016\/j.leukres.2015.04.005_bib0310","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2967\/jnumed.111.101006","article-title":"Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies","volume":"53","author":"Erba","year":"2012","journal-title":"J Nucl Med"},{"issue":"September (201)","key":"10.1016\/j.leukres.2015.04.005_bib0315","first-page":"201ra118","article-title":"Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia","volume":"5","author":"Gutbrodt","year":"2013","journal-title":"Sci Transl Med"},{"issue":"August (34)","key":"10.1016\/j.leukres.2015.04.005_bib0320","doi-asserted-by":"crossref","first-page":"21769","DOI":"10.1074\/jbc.273.34.21769","article-title":"Design and use of a phage display library human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel","volume":"273","author":"Pini","year":"1998","journal-title":"J Biol Chem"},{"issue":"December (5)","key":"10.1016\/j.leukres.2015.04.005_bib0325","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ijc.2910590507","article-title":"The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis","volume":"59","author":"Castellani","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1016\/j.leukres.2015.04.005_bib0330","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.leukres.2009.06.025","article-title":"Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma","volume":"33","author":"Schliemann","year":"2009","journal-title":"Leuk Res"},{"issue":"July (1)","key":"10.1016\/j.leukres.2015.04.005_bib0335","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood.V94.1.192.413k22_192_198","article-title":"A high-affinity human antibody that targets tumoral blood vessels","volume":"94","author":"Tarli","year":"1999","journal-title":"Blood"},{"issue":"January (2)","key":"10.1016\/j.leukres.2015.04.005_bib0340","first-page":"347","article-title":"Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis","volume":"59","author":"Viti","year":"1999","journal-title":"Cancer Res"},{"issue":"November (1)","key":"10.1016\/j.leukres.2015.04.005_bib0345","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ijc.10662","article-title":"Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin","volume":"102","author":"Borsi","year":"2002","journal-title":"Int J Cancer"},{"issue":"July (7)","key":"10.1016\/j.leukres.2015.04.005_bib0350","first-page":"1127","article-title":"Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature","volume":"47","author":"Tijink","year":"2006","journal-title":"J Nucl Med"},{"issue":"February (2)","key":"10.1016\/j.leukres.2015.04.005_bib0355","first-page":"571","article-title":"Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer","volume":"9","author":"Santimaria","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"June (11\u201312)","key":"10.1016\/j.leukres.2015.04.005_bib0360","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.drudis.2012.01.007","article-title":"Immunocytokines: a novel class of potent armed antibodies","volume":"17","author":"Pasche","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.leukres.2015.04.005_bib0365","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood.V99.5.1659","article-title":"Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix","volume":"99","author":"Carnemolla","year":"2002","journal-title":"Blood"},{"issue":"October (10)","key":"10.1016\/j.leukres.2015.04.005_bib0370","first-page":"2551","article-title":"Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy","volume":"4","author":"Dolman","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"October (20)","key":"10.1016\/j.leukres.2015.04.005_bib0375","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1158\/1078-0432.CCR-07-5041","article-title":"Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy","volume":"14","author":"Marlind","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"April (4)","key":"10.1016\/j.leukres.2015.04.005_bib0380","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1039\/c0ib00099j","article-title":"Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation","volume":"3","author":"Frey","year":"2011","journal-title":"Integr Biol"},{"issue":"April (8)","key":"10.1016\/j.leukres.2015.04.005_bib0385","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V95.8.2637","article-title":"Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia","volume":"95","author":"Padro","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.04.005_bib0390","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.04.005_bib0395","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"issue":"February (3)","key":"10.1016\/j.leukres.2015.04.005_bib0400","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.04.005_bib0405","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1158\/1078-0432.CCR-1087-3","article-title":"Studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response","volume":"10","author":"Gluck","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2015.04.005_bib0410","first-page":"1002","article-title":"Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2","volume":"88","author":"Golay","year":"2003","journal-title":"Haematologica"},{"issue":"October (20)","key":"10.1016\/j.leukres.2015.04.005_bib0415","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1158\/1078-0432.CCR-12-0456","article-title":"A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders","volume":"18","author":"Timmerman","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"November (10)","key":"10.1016\/j.leukres.2015.04.005_bib0420","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.4049\/jimmunol.171.10.5051","article-title":"IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2","volume":"171","author":"Jackaman","year":"2003","journal-title":"J Immunol"},{"issue":"July (2)","key":"10.1016\/j.leukres.2015.04.005_bib0425","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/sj.bjc.6603857","article-title":"Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12","volume":"97","author":"Barker","year":"2007","journal-title":"Br J Cancer"},{"issue":"December (13)","key":"10.1016\/j.leukres.2015.04.005_bib0430","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1084\/jem.20130678","article-title":"Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection","volume":"210","author":"Vom Berg","year":"2013","journal-title":"J Exp Med"},{"issue":"September (17)","key":"10.1016\/j.leukres.2015.04.005_bib0435","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/cncr.25156","article-title":"High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma","volume":"116","author":"Weide","year":"2010","journal-title":"Cancer"},{"issue":"December (23)","key":"10.1016\/j.leukres.2015.04.005_bib0440","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1158\/1078-0432.CCR-06-1571","article-title":"A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma","volume":"12","author":"Khan","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"May (5)","key":"10.1016\/j.leukres.2015.04.005_bib0445","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jcp.2006.038661","article-title":"Angiogenesis in nodal B cell lymphomas: a high throughput study","volume":"60","author":"Tzankov","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.leukres.2015.04.005_bib0450","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Ma","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.leukres.2015.04.005_bib0455","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1158\/1078-0432.CCR-08-0157","article-title":"The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer","volume":"14","author":"Wagner","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.leukres.2015.04.005_bib0460","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2326-6066.CIR-13-0206","article-title":"Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses","volume":"2","author":"Weide","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"February (2)","key":"10.1016\/j.leukres.2015.04.005_bib0465","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.11702","article-title":"Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma","volume":"93","author":"Tzankov","year":"2008","journal-title":"Haematologica"},{"issue":"April (4)","key":"10.1016\/j.leukres.2015.04.005_bib0470","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2567.2011.03539.x","article-title":"T regulatory cells in B-cell malignancy \u2013 tumour support or kiss of death?","volume":"135","author":"Lindqvist","year":"2012","journal-title":"Immunology"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615001125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615001125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T13:24:55Z","timestamp":1717853095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615001125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0145212615001125"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.04.005","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}